GlassScriptPhysician profile
Andrew W Mcbride
NPI 1275574329
$1,052.95
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $148 · 2021: $29.16 · 2022: $149 · 2023: $410 · 2024: $20.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.60 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $353.30 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Boston Scientific Corporation | $175.10 | 2019-2023 | Upsylon |
| Axonics, INC. | $164.31 | 2020-2022 | |
| Caldera Medical, INC | $130.60 | 2019-2021 | |
| Abbvie INC. | $72.21 | 2023 | |
| Allergan, INC. | $32.84 | 2019 | |
| Abc Home Medical Supply, INC. | $30.80 | 2022 | |
| Antares Pharma, INC. | $18.15 | 2022 | |
| Therapeuticsmd, INC. | $16.28 | 2019 | |
| Dentsply Ih Ab | $16.12 | 2023 | Lofric |
| Pfizer INC. | $15.52 | 2019 | |
| Sumitomo Pharma America, INC. | $14.43 | 2023 | Gemtesa |
| Urovant Sciences INC | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.